{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:02:33Z","timestamp":1768410153666,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cortical deposition of \u03b2-amyloid (A\u03b2) plaque is one of the main hallmarks of Alzheimer\u2019s disease (AD). While A\u03b2 positivity has been the main concern so far, predicting whether A\u03b2 (\u2212) individuals will convert to A\u03b2 (+) has become crucial in clinical and research aspects. In this study, we aimed to develop a classifier that predicts the conversion from A\u03b2 (\u2212) to A\u03b2 (+) using artificial intelligence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were obtained from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) cohort regarding patients who were initially A\u03b2 (\u2212). We developed an artificial neural network-based classifier with baseline age, gender, <jats:italic>APOE<\/jats:italic> \u03b54 genotype, and global and regional standardized uptake value ratios (SUVRs) from positron emission tomography. Ten times repeated 10-fold cross-validation was performed for model measurement, and the feature importance was assessed. To validate the prediction model, we recruited subjects at the Samsung Medical Center (SMC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 229 participants (53 converters) from the ADNI dataset and a total of 40 subjects (10 converters) from the SMC dataset were included. The average area under the receiver operating characteristic values of three developed models are as follows: Model 1 (age, gender, <jats:italic>APOE<\/jats:italic> \u03b54) of 0.674, Model 2 (age, gender, <jats:italic>APOE<\/jats:italic> \u03b54, global SUVR) of 0.814, and Model 3 (age, gender, <jats:italic>APOE<\/jats:italic> \u03b54, global and regional SUVR) of 0.841. External validation result showed an AUROC of 0.900.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We developed prediction models regarding A\u03b2 positivity conversion. With the growing recognition of the need for earlier intervention in AD, the results of this study are expected to contribute to the screening of early treatment candidates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01067-8","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T04:04:50Z","timestamp":1662955490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Predicting conversion of brain \u03b2-amyloid positivity in amyloid-negative individuals"],"prefix":"10.1186","volume":"14","author":[{"given":"Chae Jung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younghoon","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeong Sim","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyemin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyejoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"issue":"2","key":"1067_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"issue":"5580","key":"1067_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science."},{"issue":"22","key":"1067_CR3","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305\u201316.","journal-title":"JAMA."},{"issue":"7","key":"1067_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1212\/WNL.0b013e318246d67a","volume":"78","author":"G Chetelat","year":"2012","unstructured":"Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology. 2012;78(7):477\u201384.","journal-title":"Neurology."},{"issue":"6","key":"1067_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1212\/WNL.0b013e318245d295","volume":"78","author":"KM Rodrigue","year":"2012","unstructured":"Rodrigue KM, Kennedy KM, Devous MD Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. Beta-amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78(6):387\u201395.","journal-title":"Neurology."},{"issue":"4","key":"1067_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1067_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):95.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1067_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):311\u201321.","journal-title":"N Engl J Med"},{"key":"1067_CR9","first-page":"5380346","volume":"2020","author":"AE Oxford","year":"2020","unstructured":"Oxford AE, Stewart ES, Rohn TT. Clinical trials in Alzheimer\u2019s disease: a hurdle in the path of remedy. Int J Alzheimers Dis. 2020;2020:5380346.","journal-title":"Int J Alzheimers Dis"},{"issue":"1","key":"1067_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13195-020-00614-5","volume":"12","author":"G Novak","year":"2020","unstructured":"Novak G, Streffer JR, Timmers M, Henley D, Brashear HR, Bogert J, et al. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer\u2019s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimers Res Ther. 2020;12(1):58.","journal-title":"Alzheimers Res Ther"},{"issue":"17","key":"1067_CR11","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/WNL.0000000000005354","volume":"90","author":"SM Landau","year":"2018","unstructured":"Landau SM, Horng A, Jagust WJ. Alzheimer\u2019s Disease Neuroimaging Initiative. Memory decline accompanies subthreshold amyloid accumulation. Neurology. 2018;90(17):e1452\u2013e60.","journal-title":"Neurology."},{"issue":"19","key":"1067_CR12","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924\u201338.","journal-title":"JAMA."},{"key":"1067_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.dadm.2016.07.002","volume":"4","author":"PS Insel","year":"2016","unstructured":"Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, et al. Assessing risk for preclinical beta-amyloid pathology with APOE, cognitive, and demographic information. Alzheimers Dement (Amst). 2016;4:76\u201384.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"15","key":"1067_CR14","doi-asserted-by":"publisher","first-page":"e1745","DOI":"10.1212\/WNL.0000000000007231","volume":"92","author":"LA Cannon-Albright","year":"2019","unstructured":"Cannon-Albright LA, Foster NL, Schliep K, Farnham JM, Teerlink CC, Kaddas H, et al. Relative risk for Alzheimer disease based on complete family history. Neurology. 2019;92(15):e1745\u2013e53.","journal-title":"Neurology."},{"issue":"1","key":"1067_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13195-021-00787-7","volume":"13","author":"SE Kim","year":"2021","unstructured":"Kim SE, Lee B, Jang H, Chin J, Khoo CS, Choe YS, et al. Cognitive trajectories of patients with focal ss-amyloid deposition. Alzheimers Res Ther. 2021;13(1):48.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"1067_CR16","doi-asserted-by":"publisher","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","volume":"96","author":"WJ Jagust","year":"2021","unstructured":"Jagust WJ, Landau SM. Temporal dynamics of \u03b2-amyloid accumulation in aging and Alzheimer disease. Neurology. 2021;96(9):e1347\u2013e57.","journal-title":"Neurology."},{"issue":"7","key":"1067_CR17","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1007\/s00259-014-2753-3","volume":"41","author":"SM Landau","year":"2014","unstructured":"Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer\u2019s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41(7):1398\u2013407.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1067_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u201315 e1-4.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1067_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13550-017-0277-0","volume":"7","author":"SP Rowe","year":"2017","unstructured":"Rowe SP, Javadi MS, Allaf ME, Gorin MA. Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality? EJNMMI Res. 2017;7(1):34.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1067_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13550-018-0456-7","volume":"8","author":"MR Battle","year":"2018","unstructured":"Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8(1):107.","journal-title":"EJNMMI Res"},{"issue":"8","key":"1067_CR21","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s00259-019-04596-x","volume":"47","author":"SH Cho","year":"2020","unstructured":"Cho SH, Choe YS, Kim HJ, Jang H, Kim Y, Kim SE, et al. A new Centiloid method for (18)F-florbetaben and (18)F-flutemetamol PET without conversion to PiB. Eur J Nucl Med Mol Imaging. 2020;47(8):1938\u201348.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1067_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, Koeppe RA, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021;13(1):99.","journal-title":"Alzheimers Res Ther"},{"key":"1067_CR23","volume-title":"Adam: a method for stochastic optimization","author":"DP Kingma","year":"2017","unstructured":"Kingma DP, Ba J. Adam: a method for stochastic optimization; 2017. https:\/\/arxiv.org\/abs\/1412.6980. Accessed 1 Jan 2022"},{"key":"1067_CR24","volume-title":"Batch normalization: accelerating deep network training by reducing internal covariate shift","author":"S Ioffe","year":"2015","unstructured":"Ioffe S, Szegedy C. Batch normalization: accelerating deep network training by reducing internal covariate shift; 2015. https:\/\/arxiv.org\/abs\/1502.03167. Accessed 1 Jan 2022"},{"key":"1067_CR25","volume-title":"Consistent individualized feature attribution for tree ensembles","author":"SM Lundberg","year":"2018","unstructured":"Lundberg SM, Erion GG, Lee SI. Consistent individualized feature attribution for tree ensembles; 2018. https:\/\/arxiv.org\/abs\/1802.03888. Accessed 1 Jan 2022"},{"key":"1067_CR26","volume-title":"Model-agnostic interpretability of machine learning","author":"MT Ribeiro","year":"2016","unstructured":"Ribeiro MT, Singh S, Guestrin C. Model-agnostic interpretability of machine learning; 2016. https:\/\/arxiv.org\/abs\/1606.05386. Accessed 1 Jan 2022"},{"key":"1067_CR27","volume-title":"Captum: a unified and generic model interpretability library for PyTorch","author":"N Kokhlikyan","year":"2020","unstructured":"Kokhlikyan N, Miglani V, Martin M, Wang E, Alsallakh B, Reynolds J, et al. Captum: a unified and generic model interpretability library for PyTorch; 2020. https:\/\/arxiv.org\/abs\/2009.07896. Accessed 1 Jan 2022"},{"key":"1067_CR28","volume-title":"Axiomatic attribution for deep networks","author":"M Sundararajan","year":"2017","unstructured":"Sundararajan M, Taly A, Yan Q. Axiomatic attribution for deep networks; 2017. https:\/\/arxiv.org\/abs\/1703.01365"},{"issue":"5","key":"1067_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.22608","volume":"70","author":"AG Vlassenko","year":"2011","unstructured":"Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011;70(5):857\u201361.","journal-title":"Ann Neurol"},{"issue":"20","key":"1067_CR30","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1212\/01.wnl.0000435556.21319.e4","volume":"81","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20):1732\u201340.","journal-title":"Neurology."},{"issue":"10","key":"1067_CR31","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","volume":"80","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain beta-amyloid load approaches a plateau. Neurology. 2013;80(10):890\u20136.","journal-title":"Neurology."},{"issue":"12","key":"1067_CR32","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00259-020-04773-3","volume":"47","author":"MS Baek","year":"2020","unstructured":"Baek MS, Cho H, Lee HS, Choi JY, Lee JH, Ryu YH, et al. Temporal trajectories of in vivo tau and amyloid-beta accumulation in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47(12):2879\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"19","key":"1067_CR33","doi-asserted-by":"publisher","first-page":"e1809","DOI":"10.1212\/WNL.0000000000006469","volume":"91","author":"ME Farrell","year":"2018","unstructured":"Farrell ME, Chen X, Rundle MM, Chan MY, Wig GS, Park DC. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology. 2018;91(19):e1809\u2013e21.","journal-title":"Neurology."},{"key":"1067_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2021.06.014","volume":"106","author":"J Pfeil","year":"2021","unstructured":"Pfeil J, Hoenig MC, Doering E, van Eimeren T, Drzezga A, Bischof GN, et al. Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer\u2019s disease. Neurobiol Aging. 2021;106:119\u201329.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1067_CR35","doi-asserted-by":"publisher","first-page":"fcaa007","DOI":"10.1093\/braincomms\/fcaa007","volume":"2","author":"PS Insel","year":"2020","unstructured":"Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. Neuroanatomical spread of amyloid beta and tau in Alzheimer\u2019s disease: implications for primary prevention. Brain Commun. 2020;2(1):fcaa007.","journal-title":"Brain Commun"},{"issue":"12","key":"1067_CR36","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14(12):1565\u201371.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01067-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01067-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01067-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T04:06:51Z","timestamp":1662955611000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01067-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01067-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board at Samsung Medical Center approved this study, and informed consent was obtained from the patients and caregivers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}